News

The acquired site, through its enhanced manufacturing capabilities, will help Johnson to meet increasing demand for custom pharmaceutical services and active ingredients. Johnson Matthey fine chemicals division director

GNbAC1 is said to be the first drug being developed to address a causal factor of the disease, and holds the potential to radically change the way MS

As part of an ongoing trial at the Jenner Institute at Oxford University, all the adult volunteers were earlier administered an experimental Ebola vaccine being developed by GSK

Novartis had been granted exclusive license in 2010, to develop and commercialize binimetinib. Designed specifically for cancer patients, the binimetinib is currently advancing in three Phase 3 clinical

Financial terms of the transaction were not disclosed by both the companies, however, sources familiar with the development have been cited by Reuters as saying that the deal

BAY 81-8973 is a full-length recombinant factor VIII which has demonstrated clinical evidence of efficacy when used for prophylaxis twice or three times per week, with standard dosages.

Designed to slow down tumor growth, the FPA144 prevents the binding of fibroblast growth factors to FGF receptor 2b (FGFR2b) and is being developed initially as a monotherapy

Under the deal, Pfizer will review medicines that are currently under development to find substances with a probable or high risk of abuse in sport. The company will

Reassuring Member States over safety of flu vaccine, the review conducted by the committee found that the vaccine was safe for administration in vaccination campaigns. The review follows